Share Icon Health Study Area: Cardiovascular Disease Chevron Icon Health Study Area: Genitourinary For Patients Health Study Area: Lung Cancer Page Icon Phone Icon For Caregivers Health Study Area: AutoImmune Disease Health Study Area: Melanoma Location Icon Print YouTube Icon For Parents Health Study Area: Lung Cancer Print Created with Sketch. Help Icon Green Check Icon Search Icon Instagram Created with sketchtool. Direction Arrow Icon Error Icon For Parents Health Study Area: Blood Cancer Help Icon Health Study Area: NASH Gender Both Bookmark Icon Health Study Area: Melanoma Created with Sketch. Glossary Print Health Study Area: Blood Cancer Health Study Area: Genitourinary Health Study Area: Gastrointestinal Cancer Mobile Menu Icon Created with Sketch. Health Study Area: Cardiovascular Disease Health Study Area: Women's Cancer Communities Map Icon Created with Sketch. For Caregivers Health Study Area: Fibrosis Health Study Area: AutoImmune Disease FAQs Health Study Area: Head and Neck Cancer Created with Sketch. For Clinicians Chevron Right Icon Gender Female Health Study Area: Breast Cancer Direction Arrow Icon Gender Both Right Arrow Icon LinkedIn Icon Green Check Icon Gender Male Health Study Area: Fibrosis For Patients Twitter Icon Email Icon Facebook Icon Health Study Area: Gastrointestinal Cancer Health Study Area: Head and Neck Cancer For Clinicians External Link Icon

Menu

Search BMS Clinical Trials
BMS Recruiting Study icon

Recruiting

Trial ID CA243-0001  |   NCT06997029

A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors

Summary

  • Phase 1
  • Male and Female Gender icon
  • 18+
    Age Range
  • 13
    Locations
  • BMS Recruiting Study icon
    Recruiting

Overview

The purpose of this study is to assess BMS-986500 as monotherapy in advanced solid tumors and as combination therapy in CDK4/6 inhibitor pre-treated advanced breast cancer.

print Print
email Email

Nearest Recruiting Site

Key Eligibility Criteria

Inclusion Criteria

Inclusion Criteria Icon img
:
  • Participants must be ≥ 18 years of age.
    1. Participants must have histologically confirmed diagnosis of a locally advanced, unresectable, or metastatic solid tumor malignancy.
      1. Participants must have a measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
        1. Participants must have a stable Eastern Cooperative Oncology Group Performance Status of 0 or 1.
          1. For Part 2A only, participants must have CCNE1-amplified ovarian cancer

            Exclusion Criteria

            Exclusion Criteria Icon
            :
            • Participants must not have an active brain metastasis.
              1. Participants must not have impaired cardiac function or clinically significant cardiac disease.
                1. Participants must not have bleeding disorder or any history of clinically significant bleeding within the prior 3 months.
                  1. Participants must not have Grade ≥ 2 peripheral neuropathy.
                    Additional Information *
                    • Other protocol-defined Inclusion/Exclusion criteria apply.

                      Treatment Options

                      Study Arms

                      ASSIGNED INTERVENTION

                      Study Arms

                      Experimental: Part 1A Monotherapy Dose Escalation

                      ASSIGNED INTERVENTION
                      • Drug: BMS-986500

                      Study Arms

                      Experimental: Part 1B Combination Dose Escalation

                      ASSIGNED INTERVENTION
                      • Drug: BMS-986500, Palbociclib, Fulvestrant

                      Study Arms

                      Experimental: Part 1C Monotherapy Pharmacodynamic (PD) Sub-study

                      ASSIGNED INTERVENTION
                      • Drug: BMS-986500

                      Study Arms

                      Experimental: Part 2A Monotherapy Dose Expansion

                      ASSIGNED INTERVENTION
                      • Drug: BMS-986500

                      Study Arms

                      Experimental: Part 2B Combination Dose Expansion

                      ASSIGNED INTERVENTION
                      • Drug: BMS-986500, Palbociclib, Fulvestrant
                      Take the first step to see if you Match to a Clinical Trial – Check Your Eligibility
                      Check Your Eligibility
                      Answer some questions about Your health to see if you may match to this trial
                      Match to a Trial
                      If you are a match, click on the study to see the list of study site locations
                      Select a Study Site Location
                      Select a study site location that is convenient for you
                      Register
                      Provide your contact details for the study site to connect with you.

                      Help us enhance your website experience! Share your feedback with our team at BMS Clinical Trials to improve yours and others’ experience. Thank you